BioSpace News Archive

Tris Pharma, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients six years and older.

Citius Pharmaceuticals, Inc. today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.

Tandem Diabetes Care, Inc. and Dexcom, Inc., announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems.

Jaguar Health, Inc. today announced that the company’s out-licensing agreement with Magdalena Biosciences, Inc. (“Magdalena”), the joint venture formed by Jaguar and Filament Health Corp.

Tharimmune, Inc. announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego.

MannKind Corporation announced that it has agreed to in-license iSPERSE™ technology from Pulmatrix for certain indications in exchange for an out-license of MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine for migraine treatment.

Protalix BioTherapeutics, Inc. announced that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California.

Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.

Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced the formation of its distinguished Scientific Advisory Board.

Grey Wolf Therapeutics today announced that the first clinical data for the company’s lead immuno-oncology candidate, GRWD5769, will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.